Fundsmith Joins Hargreaves Lansdown’s Vantage Platform
Fundsmith, founded by Terry Smith, announces that the Fundsmith Equity Fund is now available on Hargreaves Lansdown’s Vantage Service, the UK’s biggest retail investment platform. In a research note, Hargreaves Lansdown noted Terry Smith’s long-term, high conviction approach and the Fund’s impressive performance since launch. As at 31 December 2013, the Vantage Service had over 584,000 clients holding £40.9 billion of assets.
The Fundsmith Equity Fund is also available on the following platforms:
Ascentric, AXA Elevate, Cofunds Institutional, Cofunds Retail, Fidelity FundsNetwork, Moventum, Novia, Nucleus, Pershing Nexus, Skandia, Standard Life, Transact, and True Potential.
The Fundsmith Equity Fund, launched in November 2010, offers investors a high quality, concentrated portfolio of 20-30 resilient global growth companies which are held for the long term.
The T Class Accumulation Shares, in the three years ending 31 October 2013, delivered a compound return of 17.3% p.a. and a total return of 61.2% outperforming the MSCI World Index (GBP, Gross) by 19.4%, and the average IMA Global Equity Fund by 31.7%, placing the fund 4th in the IMA Global Growth Sector out of 244 funds.
Fundsmith is due to launch a new fund, Fundsmith Emerging Equities Trust PLC (“FEET”). FEET will be an investment trust and will invest in companies that have the same characteristics as the Fundsmith Equity Fund but are mostly headquartered and listed in emerging markets. Full details will be made available in due course.
-Ends-
For further information please contact:
Greenbrook Communications
Charlotte Balbirnie, Georgiana Brunner
+44 (0)20 7952 2000, +44 (0)7989 528421
cbalbirnie@greenbrookpr.com, gbrunner@greenbrookpr.com
About Fundsmith:
Fundsmith is a fund management company established in 2010 by Terry Smith and is the main vehicle for Terry’s own investments. The business is 100% owned and controlled by its partners, who have worked closely together over many years, and is headquartered in London with an office in Connecticut, USA. Fundsmith also offers its own stocks and shares ISA. Fundsmith is authorised and regulated by the Financial Services Authority.
No Fees for Performance
No Up Front Fees
No Nonsense
No Debt or Derivatives
No Shorting
No Market Timing
No Index Hugging
No Trading
No Hedging
An English language prospectus for the Fundsmith Equity Fund is available on request and via the Fundsmith website and investors should consult this document before purchasing units in the fund. Past performance is not necessarily a guide to future performance. The value of investments and the income from them may fall as well as rise and be affected by changes in exchange rates, and you may not get back the amount of your original investment. Fundsmith LLP does not offer investment advice or make any recommendations regarding the suitability of its product. This financial promotion is intended for UK residents only and is communicated by Fundsmith LLP which is authorised and regulated by the Financial Conduct Authority.
The Fundsmith Emerging Equities Trust is due to launch in 2014 and full details will be made available in due course.
The content of this announcement has been approved for the purposes of section 21 of the Financial Services and Markets Act 2000 by Fundsmith LLP ("Fundsmith"), which is authorised and regulated by the Financial Conduct Authority. Reliance on this announcement for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
This announcement is not intended to constitute, and should not be construed as, investment advice. This announcement relating to Fundsmith Emerging Equities Trust plc ("FEET") does not constitute or form part of, and should not be construed as an offer or invitation to sell or issue or any solicitation of any offer to purchase or subscribe for any securities in FEET in any jurisdiction. Neither this announcement, nor any part of it nor anything contained or referred to in it, nor the fact of its distribution, should form the basis of, or be relied on in any connection with, or act as an inducement in relation to a decision to purchase or subscribe for or enter into any contract or make any other commitment whatsoever in relation to any such securities. In particular, details included in this announcement are subject to updating, revision, further verification and amendment and refer to events as having occurred which have not occurred at the date of this announcement but which are expected to happen in the future. This announcement does not constitute a recommendation regarding the securities of FEET.
Recipients of this announcement who are considering acquiring ordinary shares in FEET (the "Ordinary Shares") following publication of a prospectus in relation to those Ordinary Shares are reminded that any such acquisition must be made only on the basis of the information contained in the prospectus which may be different from the information contained in this announcement.
The Ordinary Shares have not been, nor will they be, registered under the US Securities Act of 1933, as amended or with any securities regulatory authority of any state or other jurisdiction of the United States or under the applicable securities laws of Canada, Australia, the Republic of South Africa or Japan or any other jurisdiction that is a member state of the European Economic Area (other than the United Kingdom). Subject to certain exceptions, the Ordinary Shares may not be offered or sold in the United States, Canada, Australia, the Republic of South Africa, Japan, or any other jurisdiction that is a member state of the European Economic Area (other than the United Kingdom) or to or for the account or benefit of any national, resident or citizen of Canada, Australia, the Republic of South Africa, Japan or any person located in the United States. The distribution of this announcement in other jurisdictions may be restricted by law and the persons into whose possession this announcement comes should inform themselves about, and observe, any such restrictions.